USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.

The oral formulation is marketed in the U.S. under the tradename Fanapt™ by Novartis Pharmaceuticals Corporation pursuant to an agreement between Vanda and Novartis Pharma AG, which was entered into on October 12, 2009.  Novartis is responsible for the commercialization and further clinical development activities of Fanapt™ in the U.S. and Canada, including the development and commercialization of the long-acting injectable (or depot) formulation of Fanapt™.  Vanda retains rights to commercialize Fanapt™ oral and depot formulations outside the U.S. and Canada.

SOURCE Vanda Pharmaceuticals Inc.